MicroRNA 483-3p overexpression unleashes invasive growth of metastatic colorectal cancer via NDRG1 downregulation and ensuing activation of the ERBB3/AKT axis.


Journal

Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230

Informations de publication

Date de publication:
07 2023
Historique:
revised: 07 02 2023
received: 04 11 2022
accepted: 27 02 2023
medline: 7 7 2023
pubmed: 3 3 2023
entrez: 2 3 2023
Statut: ppublish

Résumé

In colorectal cancer, the mechanisms underlying tumor aggressiveness require further elucidation. Taking advantage of a large panel of human metastatic colorectal cancer xenografts and matched stem-like cell cultures (m-colospheres), here we show that the overexpression of microRNA 483-3p (miRNA-483-3p; also known as MIR-483-3p), encoded by a frequently amplified gene locus, confers an aggressive phenotype. In m-colospheres, endogenous or ectopic miRNA-483-3p overexpression increased proliferative response, invasiveness, stem cell frequency, and resistance to differentiation. Transcriptomic analyses and functional validation found that miRNA-483-3p directly targets NDRG1, known as a metastasis suppressor involved in EGFR family downregulation. Mechanistically, miRNA-483-3p overexpression induced the signaling pathway triggered by ERBB3, including AKT and GSK3β, and led to the activation of transcription factors regulating epithelial-mesenchymal transition (EMT). Consistently, treatment with selective anti-ERBB3 antibodies counteracted the invasive growth of miRNA-483-3p-overexpressing m-colospheres. In human colorectal tumors, miRNA-483-3p expression inversely correlated with NDRG1 and directly correlated with EMT transcription factor expression and poor prognosis. These results unveil a previously unrecognized link between miRNA-483-3p, NDRG1, and ERBB3-AKT signaling that can directly support colorectal cancer invasion and is amenable to therapeutic targeting.

Identifiants

pubmed: 36862005
doi: 10.1002/1878-0261.13408
pmc: PMC10323897
doi:

Substances chimiques

Proto-Oncogene Proteins c-akt EC 2.7.11.1
MicroRNAs 0
Transcription Factors 0
MIRN483 microRNA, human 0

Banques de données

RefSeq
['NM_001374847.1']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1280-1301

Subventions

Organisme : Cancer Research UK
ID : A28223
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A26825
Pays : United Kingdom

Informations de copyright

© 2023 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.

Références

J Biol Chem. 2017 Aug 4;292(31):12772-12782
pubmed: 28615452
Cell Stem Cell. 2011 Oct 4;9(4):357-65
pubmed: 21982235
Trends Biochem Sci. 2019 Aug;44(8):688-700
pubmed: 31085088
Cancer Res. 2017 Jan 1;77(1):86-99
pubmed: 27793840
Nat Rev Cancer. 2012 Jul 12;12(8):553-63
pubmed: 22785351
Nat Med. 2014 Jul;20(7):769-77
pubmed: 24859528
Nature. 2011 Jan 20;469(7330):415-8
pubmed: 21113151
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Nat Cell Biol. 2004 Oct;6(10):931-40
pubmed: 15448698
J Immunol Methods. 2009 Aug 15;347(1-2):70-8
pubmed: 19567251
Cell Rep. 2021 Jul 27;36(4):109455
pubmed: 34320350
Cell Stem Cell. 2014 Mar 6;14(3):306-21
pubmed: 24607405
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
Oncogene. 2008 Jan 3;27(1):107-15
pubmed: 17599044
Clin Cancer Res. 2018 Feb 15;24(4):807-820
pubmed: 28974546
Mol Syst Biol. 2005;1:2005.0008
pubmed: 16729043
Cancer Discov. 2011 Nov;1(6):508-23
pubmed: 22586653
J Cell Sci. 2003 Apr 1;116(Pt 7):1175-86
pubmed: 12615961
Nat Rev Clin Oncol. 2021 Aug;18(8):506-525
pubmed: 33864051
Nat Rev Clin Oncol. 2017 Oct;14(10):611-629
pubmed: 28397828
Cancer Discov. 2021 Jul;11(7):1644-1660
pubmed: 33820776
Nat Genet. 2017 Jan;49(1):65-74
pubmed: 27869826
Nature. 2015 Sep 24;525(7570):469-78
pubmed: 26399828
Cancer Res. 2010 Apr 15;70(8):3140-9
pubmed: 20388800
Oncogene. 2019 Jan;38(5):699-715
pubmed: 30171257
Oncogene. 2014 Jun 12;33(24):3172-82
pubmed: 23851495
J Vis Exp. 2015 Nov 20;(105):
pubmed: 26649463
Sci Transl Med. 2015 Jan 28;7(272):272ra12
pubmed: 25632036
Biochim Biophys Acta. 2014 Jan;1845(1):1-19
pubmed: 24269900
Science. 2003 Mar 14;299(5613):1753-5
pubmed: 12637750
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Cancer Cell. 2014 Mar 17;25(3):282-303
pubmed: 24651011
Genes Dev. 2021 Jun;35(11-12):787-820
pubmed: 34074695
Cancer Res. 2014 Mar 15;74(6):1857-69
pubmed: 24448239
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13427-32
pubmed: 18765800
J Biol Chem. 2016 Jan 15;291(3):1029-52
pubmed: 26534963
Mol Cell Biol. 2001 Dec;21(23):8189-96
pubmed: 11689707
Free Radic Biol Med. 2020 Sep;157:154-175
pubmed: 31132412
PLoS One. 2008 Aug 06;3(8):e2888
pubmed: 18682804
Nat Commun. 2013;4:2956
pubmed: 24356439
Nat Rev Cancer. 2005 Sep;5(9):744-9
pubmed: 16148886
NPJ Syst Biol Appl. 2017 Jan 05;3:16034
pubmed: 28725482
Nat Rev Mol Cell Biol. 2020 Jun;21(6):341-352
pubmed: 32300252
Cell Stem Cell. 2016 Dec 1;19(6):725-737
pubmed: 27641305
Nat Cell Biol. 2019 Jan;21(1):102-112
pubmed: 30602760
Nat Rev Cancer. 2021 May;21(5):325-338
pubmed: 33547455
Cancer Res. 2000 Feb 1;60(3):749-55
pubmed: 10676663
Oncogene. 2021 Oct;40(41):5993-6006
pubmed: 34385595
Nat Commun. 2021 May 3;12(1):2498
pubmed: 33941777
Nat Rev Cancer. 2017 Feb;17(2):79-92
pubmed: 28050011
Mod Pathol. 2007 Dec;20(12):1286-97
pubmed: 17906616
Clin Cancer Res. 2009 Jul 15;15(14):4665-73
pubmed: 19584150

Auteurs

Ermes Candiello (E)

Laboratory of Cancer Stem Cell Research, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.

Gigliola Reato (G)

Laboratory of Cancer Stem Cell Research, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
Department of Oncology, University of Turin Medical School, Italy.

Federica Verginelli (F)

Laboratory of Cancer Stem Cell Research, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.

Gennaro Gambardella (G)

Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.
Department of Chemical Materials and Industrial Engineering, University of Naples Federico II, Italy.

Antonio D Ambrosio (A)

Laboratory of Cancer Stem Cell Research, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.

Noemi Calandra (N)

Laboratory of Cancer Stem Cell Research, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
Department of Oncology, University of Turin Medical School, Italy.

Francesca Orzan (F)

Laboratory of Cancer Stem Cell Research, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.

Antonella Iuliano (A)

Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy.

Raffaella Albano (R)

Laboratory of Cancer Stem Cell Research, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.

Francesco Sassi (F)

Translational Cancer Medicine, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.

Paolo Luraghi (P)

Laboratory of Cancer Stem Cell Research, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.

Paolo M Comoglio (PM)

IFOM, FIRC Institute of Molecular Oncology, Milan, Italy.

Andrea Bertotti (A)

Department of Oncology, University of Turin Medical School, Italy.
Translational Cancer Medicine, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.

Livio Trusolino (L)

Department of Oncology, University of Turin Medical School, Italy.
Translational Cancer Medicine, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.

Carla Boccaccio (C)

Laboratory of Cancer Stem Cell Research, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy.
Department of Oncology, University of Turin Medical School, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH